Category Specific RSS

Categories: News

ResApp’s sleep apnoea app now available on Apple App Store

Australians that are struggling to get a good night sleep can now screen their likelihood of suffering from sleep apnoea with medtech company ResApp Health (ASX: RAP) having launched their clinically tested SleepCheck app on the iPhone App Store. 

By downloading the smartphone app, SleepCheck can record and analyse breaking and snorting sounds during sleep to provide an assessment of the likelihood the user suffers from sleep apnoea. 

“We are excited to announce that SleepCheck is now available on the App Store. For the first-time, consumers have direct access to a clinical-grade, regulatory-approved screening tool for sleep apnoea,” said Resapp Managing Director, Tony Keating.

“Over a third of Australian adults do not get the duration or quality of sleep needed, which has major consequences for their health, safety and quality of life. 

“Many adults snore, and loud snoring is an important indicator of sleep apnoea, although it often is ignored. SleepCheck offers an easy way to check if there’s more to your snore.”

Clinically tested through a 308 patient study, the SleepCheck algorithms provided an accurate assessment to identify obstructive sleep apnoea when compared to a simultaneous at-home comprehensive sleep study. With the trials validated, the software was approved in Europe to be CE Marked and in Australia by the Therapeutic Goods Association. 

iPhone users can download the SleepCheck app for $7.99 (£4.99 in the UK) while ResApp expects it to make it available on Android devices later in the year. 

Once the app collects sufficient data, users are provided with a low, medium, high or very high rating to classify their risk of having sleep apnoea and provided with recommended next steps. 

Alongside SleepCheck, ResApp has another smartphone app for the diagnosis and management of respiratory diseases. To develop the project further, the Company has partnered with global health products manufacturer RB to build and test a prototype.

 

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform

Semiconductor Market Opens Door to Global Expansion Australian tech innovator Nanoveu (ASX:NVU) has locked in…

2 days ago

Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing

ASX-listed semiconductor company Archer Materials (ASX:AXE) has hit a key technical milestone, demonstrating that its…

2 days ago

EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges

PFAS Regulation Drives Urgent Market Need As global pressure mounts to tackle man-made chemicals, The…

3 days ago

RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site

In a move that underlines the growing role of automation in the resources sector, RocketDNA…

1 week ago

BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote

Australia’s broadcast technology sector is experiencing rapid global expansion, driven by demand for IP video…

3 weeks ago

AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain

Advanced Manufacturing Hits U.S. Soil AML3D Limited (ASX:AL3), a leader in Wire-arc Additive Manufacturing (WAM®),…

3 weeks ago